Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment with Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients.

Andrea LombardiGiulia VieroSimone VillaSimona Biscarini Emanuele PalombaCecilia AzzaràNathalie IannottiBianca MarianiCamilla GenoveseMara TomaselloAnna TonizzoMarco FavaAntonia Grazia ValzanoLetizia Corinna MorlacchiMaria Francesca DonatoGiuseppe CastellanoRamona CassinMaria CarrabbaAntonio MuscatelloAndrea GoriAlessandra Bandera

Published in: Biomedicines (2023)

Early treatment of SARS-CoV-2 infection with TIX/CIL showed favourable outcomes in a small group of immunocompromised patients, reporting no significant difference compared to similar patients treated with other mAbs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
sars cov
coronavirus disease
type diabetes
patient reported outcomes
extracorporeal membrane oxygenation
patient reported
mechanical ventilation